BRL-101

BRL-101自体造血干祖细胞

Report date: 2024/10/23 15:58:08

Base Information

Drug NameBRL-101
Drug Alias NameBRL-101BRL101
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Gene editing
Mechanisms of ActionStem cell replacementsBCL11A gene inhibitors
TargetsB-cell lymphoma/leukemia 11A
Therapy Area/Indicationsbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBRL Medicine Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBRL Medicine IncPorton Pharma Solutions Ltd
Inactive CompaniesN/A
Active Indicationsbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A